SAN DIEGO—The American Association for Cancer Research (AACR) is slated to honor two pivotal figures in the realms of government advocacy and patient engagement during the forthcoming AACR Annual Meeting 2026, scheduled at the San Diego Convention Center from April 17 to 22. The awards spotlight exemplary contributions facilitating cancer research advancements, each embodying leadership and unwavering dedication essential to the progress of biomedical science and patient-centered care.
Senator Susan Collins of Maine will receive the 2026 Distinguished Public Service Award, a testament to her profound impact on sustaining and expanding federal funding for cancer and biomedical research. Her tenure as Chair of the Senate Appropriations Committee marks a historic milestone as the first Republican woman to helm this influential body, an appointment consequential for NIH funding policy. During the FY 2026 budget deliberations, Senator Collins emerged as a formidable advocate against sweeping proposals to slash NIH resources by over 40%, a cut estimated to have detrimental effects on basic and translational research pivotal to cancer innovations.
Her leadership catalyzed a significant congressional pivot, with appropriations eventually increasing the NIH budget by $415 million. This fiscal turnaround underscores the critical intersection of policy acumen and scientific advocacy—a synergy vital to fueling studies ranging from molecular oncology to population-based cancer epidemiology. Her public statements uniformly underscored the premise that investments in biomedical research yield unmatched returns in public health outcomes, technological breakthroughs, and pharmaceutical innovation.
Moreover, Senator Collins’ policy endeavors extend beyond research funding into enhancing clinical and preventive frameworks. The co-authored SCREENS for Cancer Act exemplifies her proactive stance on expanding access to early detection modalities for breast and cervical cancers through the National Breast and Cervical Cancer Early Detection Program. By advocating for this program’s reauthorization and fortification, Collins supports a foundation for reducing cancer mortality via early-stage interventions, implicating crucial epidemiological surveillance and intervention efficacy.
In parallel, her introduction of the bipartisan NIH Clinical Trial Integrity Act aims to refine demographic representation in clinical trial cohorts. This legislative effort addresses systemic disparities and enhances the validity and applicability of research findings across diverse populations. By ensuring inclusivity, the act fosters precision medicine approaches that tailor interventions to genetic, environmental, and socio-economic intricacies, amplifying the translational value of clinical trials.
Contrasting with Senator Collins’ institutional approach, Jill Feldman, the recipient of the 2026 AACR Distinguished Patient Advocacy and Engagement Award, embodies grassroots leadership shaped by personal and community experiences with lung cancer. Diagnosed herself at 39 with EGFR-positive lung cancer—a mutation driving oncogenesis through aberrant epidermal growth factor receptor signaling—Feldman has transformed her journey into a worldwide advocacy crusade. Her efforts emphasize incorporating patient voices into the fabric of scientific inquiry and healthcare policy, bridging experiential knowledge with clinical and laboratory research.
Feldman’s foundational role in EGFR Resisters reflects an innovative model of patient-driven research funding, directing over $1 million to lung cancer studies targeting EGFR mutations. This organization’s strategic funding demonstrates how patient communities can meaningfully influence research priorities, fostering therapies that address molecular subtypes often neglected in broader oncology research pipelines. Additionally, Feldman’s involvement in the ECOG-ACRIN Thoracic Committee and the Department of Defense Lung Cancer Research Program exemplifies the bidirectional communication channel between advocacy groups and institutional research agendas.
A critical aspect of Feldman’s leadership lies in destigmatizing lung cancer and enhancing physician-patient communication. Her co-development of the International Association for the Study of Lung Cancer’s Language Guide underscores the importance of terminology that reduces blame, alleviates psychological burden, and fosters trust—an often overlooked component in clinical care that can markedly influence treatment adherence and quality of life. Feldman’s scholarship, including peer-reviewed publications and clinical guidelines, sets a precedent in integrating qualitative patient experience data with quantitative research frameworks.
Both honorees’ commitments resonate profoundly within the cancer research ecosystem, demonstrating different yet complementary routes to progress—policy advocacy securing vital research funding and systemic reforms, and patient engagement ensuring that the lived realities of disease shape the research questions and clinical methodologies pursued. Their recognition at the AACR Annual Meeting 2026 will not only celebrate their individual achievements but also highlight the necessity of multisectoral collaboration in the fight against cancer.
The AACR Annual Meeting serves as a preeminent forum aggregating oncology scientists, clinicians, and advocates to disseminate breakthroughs spanning genomic medicine, immunotherapy, cancer prevention, and survivorship research. The inclusion of leaders like Collins and Feldman as speakers at the Opening Ceremony on April 19 underscores the AACR’s commitment to integrating science, policy, and patient empowerment.
Senator Collins’ acknowledgment accentuates how legislative expertise and tenacity can shield the biomedical research enterprise from fiscal threats, ensuring continuity of programs that underpin fundamental discoveries, translational innovation, and ultimately, therapeutic advances. Likewise, Feldman’s recognition amplifies the crucial role of patient advocates in shaping ethical research frameworks, inclusive trial designs, and compassionate clinical care protocols that collectively improve outcomes and patient experiences.
Their stories are emblematic of the broader cancer research landscape’s complexities—a convergence of science, policy, and humanity. As the U.S. navigates funding challenges and strives to maintain global leadership in biomedical innovation, voices like Senator Collins’ play an indispensable role in safeguarding resources. Simultaneously, advocates like Feldman ensure that research remains patient-centered, equitable, and responsive to evolving community needs.
Thus, the AACR 2026 Distinguished Awards not only celebrate notable individuals but serve as a clarion call highlighting the multifaceted efforts required to sustain momentum against cancer. They reassert that progress depends equally on robust science, enlightened policy, and the authentic integration of patient perspectives, forging a future where cancer prevention, diagnosis, and treatment continue to advance.
Both awardees embody a paradigm where advocacy transcends traditional boundaries, blending political foresight with experiential insight. Their combined influence paves the way for a more holistic approach to cancer research—one that prioritizes scientific integrity, fiscal support, population diversity, and empathetic care—fundamentals essential for transformative breakthroughs that will define oncology in the coming decades.
Subject of Research: Cancer research funding and patient advocacy in biomedical innovation, with emphases on NIH appropriations, lung cancer molecular subtypes (EGFR-positive), and patient-centered clinical research.
Article Title: AACR to Honor Senator Susan Collins and Lung Cancer Advocate Jill Feldman for Pioneering Contributions to Cancer Research and Patient Advocacy at 2026 Annual Meeting
News Publication Date: Not explicitly provided in source text; inferred to be contemporary to AACR Annual Meeting 2026 (April 2026).
Web References:
- American Association for Cancer Research: https://www.aacr.org/
- AACR Annual Meeting 2026: https://www.aacr.org/meeting/aacr-annual-meeting-2026/
- Cancer Today article on Jill Feldman: https://www.cancertodaymag.org/cancer-talk/redefining-cancer-survivorship/
Keywords: AACR, cancer research funding, NIH appropriations, Susan Collins, patient advocacy, lung cancer, EGFR mutation, clinical trials diversity, biomedical innovation, cancer policy, translational research, patient-centered care
